

Alzheimer's Support

During 2020:

• GSK provided £1,000 core funding to support Alzheimer's Support, in the absence of a GSK IMPACT Award employee vote

Our support represented 0.05% of their overall income



Blood Cancer UK

During 2020:

 GSK provided funding of £9,437.00, to support the costs of medium-term needs of people affected by blood cancer during the COVID-19 pandemic, specifically looking at psychological and emotional support.

Our support represented 0.1% of their overall income



Asthma UK and British Lung Foundation Partnership*

During 2020 GSK provided funding of:

- £45,000 to support towards the cost of Year 3 Taskforce for Lung Health.
- £20,000, to support the increasing helpline capacity and provide accessible COVID-19 information for all.
- £2,499.75 to support towards funding of Asthma and COPD leaflets.

And a fee-for-service:

• £1,000 Finders Fee for members of a virtual focus group to review updates on website materials

Our support represented 0.49% of their overall income

*Patient Organisation name change and funding details in 2020:
The Taskforce funding and the Asthma and COPD leaflets were made under the name of 'British Lung Foundation' in 2019 for projects that took place in 2020 when the funding was received. The COVID-19 response funding allocation was conducted under the name 'the British Lung Foundation on behalf of the Asthma UK' and 'British Lung Foundation Partnership' as the funding was to support the British Lung Foundation's Helpline and information.



Cancer Support UK

During 2020:

• GSK provided funding of £10,000 to support with the marketing costs towards Cancer Coach during 2020.

Our support represented 1% of their overall income



Go Girls

During 2020 GSK has provided funding of:

- £5,500 to support the funding of produce short films to enable women with gynaecological cancers to manage during COVID-19 pandemic.
- £9,200 supporting women with gynaecological cancers to manage during COVID-19 pandemic

Our support represented 42% of their overall income. It was anticipated that the funding would go above 25% due to a collapse in their other fundraising streams during the 2020 pandemic year. This was approved due to exceptional circumstances.



Headway East London

During 2020:

• GSK provided £30,000 core funding to support Headway East London, as a GSK IMPACT Award Winner

Our support represented 1.65% of their overall income



Jo's Cervical Cancer Trust

During 2020 GSK provided funding of:

- £15,000, to support the cost of the Cervical Cancer Trust Helpline.
- £25,000 for various COVID-19 related activities to support website users.

Our support represented 2% of their overall income



LUPUS UK

During 2020 GSK provided funding of:

- £20,000 to support the costs of developing a series of virtual patient education
 events throughout the rest of 2020 to offer lupus patients an opportunity to gain
 important insights into their disease and how their healthcare is being affected by
 the pandemic.
- £5,000 to support with the printing costs of the book: Lupus Diagnosis & Treatment (2020 Edition).

Our support represented 3.79% of their overall income in 2020.



Meningitis Research Foundation

During 2020:

• GSK provided funding of £5,000, to support the cost of planned Meningitis Symposium series.

Our support represented 0.2% of their overall income



Multiple Sclerosis Therapy Centre - Mid Argyll

During 2020:

 GSK provided £1,000 core funding to support Multiple Sclerosis Therapy Centre -Mid Argyll, in the absence of a GSK IMPACT Award employee vote

Our support represented 0.47% of their overall income



New Life Counselling

During 2020:

 GSK provided £3,000 core funding to support New Life Counselling, as a GSK IMPACT Award Runner Up.

*Please note that the % of their total overall income that our support represented will follow in due course. It is anticipated to fall below 25%.



Ovarian Cancer Action

During 2020:

• GSK provided funding of £17,700 to support the cost of the Stay Connected Programme for the month of April.

Our support represented 1% of their overall income



Positively UK

During 2020:

 GSK provided £3,000 core funding to support Positively UK, as a GSK IMPACT Award Runner Up

Our support represented 0.5% of their overall income



Pulmonary Hypertension Association UK

During 2020 GSK provided funding of:

- £10,000 to support with the day-to-at running costs.
- £15,000 to support with the production of a video that educates patients on how to use the new CADD Solis pump and produce a training booklet to complement the video.

Our support represented 5% of their overall income



Sarcoma UK

During 2020:

• GSK provided funding of £13,550, to help fund patient information, awareness and their specialist sarcoma Support Line.

Our support represented 0.87% of their overall income



Sickle Cell Society

During 2020:

 GSK provided £10,000 core funding to support Sickle Cell Society, to support and represent people affected by sickle cell disease to improve their overall quality of life.

Our support represented 1.3% of their overall income



Target Ovarian Cancer

During 2020:

• GSK provided funding of £10,000, to support two specialist nurses who are on the frontline supporting women with ovarian cancer during and beyond the pandemic.

Our support represented 0.5% of their overall income



The Brunswick Centre

During 2020:

• GSK provided £3,000 core funding to support The Brunswick Centre, as a GSK IMPACT Award Runner Up

Our support represented 0.74% of their overall income



The Eve Appeal

During 2020:

GSK provided funding of £13,523, to support the costs of adaption of the consensus document into a) a patient-friendly written Q&A resource and b) a series of short educational films, which feature a gynaecological nurse specialist explaining the science and rationale behind the guidelines in an accessible way

Our support represented 1.2% of their overall income



Trevi House

During 2020:

 GSK provided £30,000 core funding to support Trevi House, as a GSK IMPACT Award Winner

Our support represented 1.94% of their overall income